

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicants: BERGMANN et al. Attorney Dkt. No.: 2582.022  
Serial No.: 09/889,094 Examiner: Michael D. Pak  
Filed: October 19, 2001 Group Art Unit: 1646  
Title: USE OF BLOCKING ANTI-TSH-RECEPTOR-ANTIBODIES IN THE  
THERAPY OF HYPERTHYREOSES AND MONOCLONAL ANTIBODIES  
FOR USE OF THIS TYPE

Confirmation No.: 7928

To: Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Dear Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§ 1.56, 1.97, and 1.98, Applicants hereby make of record in the instant application the documents listed on the attached Form 1449.

This Supplemental Information Disclosure Statement is filed concurrently with a Request for Continued Examination, to remove the finality of an Office Action. Accordingly, no fee for the IDS is believed due. This information is being cited out of an abundance of caution in view of the decisions in *Akron Polymer Container v. Exxel Container*, 148 F.3d 1380 (Fed. Cir. 1998) and *McKesson Information Solutions v. Bridge Medical, Inc.*, 487 F.3d 897 (Fed. Cir. 2007).


Applicants respectfully request that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning patentability of the present claims, and initial, sign, and date the enclosed Form 1449, and return a copy of the signed Form 1449 with the next U.S. Patent and Trademark communication to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By citing these references, Applicants make no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b); and (3) the information cited is, or is considered to be, in fact, prior art as defined by 35 U.S.C. § 102.

Notwithstanding any statements by Applicants, or treatment of this cited information by this or another Patent Office, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited references. An early and favorable action is hereby requested.

The Commissioner is hereby authorized to charge payment of any fees that may be required, or credit any overpayment of same, to Deposit Account No. 08-1935, Reference No. 2582.022.

Respectfully submitted,

  
Kathy Smith Dias  
Attorney for Applicant  
Registration No. 41,707

Dated: May 4, 2008  
HESLIN ROTHENBERG FARLEY & MESITI P.C.  
5 Columbia Circle  
Albany, New York 12203  
Phone: 518-452-5600 Fax: 518-452-5579